Apr 12 |
Buy Altimmune's Potential Market Disruption With Pemvidutide
|
Mar 27 |
Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
|
Mar 27 |
Altimmune, Inc. (ALT) Q4 2023 Earnings Call Transcript
|
Mar 27 |
Altimmune falls after Q4 results; obesity drug data released
|
Mar 27 |
Altimmune GAAP EPS of -$0.54 misses by $0.16
|
Mar 27 |
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 27 |
Earnings Scheduled For March 27, 2024
|
Mar 26 |
Altimmune Q4 2023 Earnings Preview
|
Mar 20 |
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
|
Mar 19 |
Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
|